
Pharma is exceptionally good at generating evidence. But evidence alone does not change clinical practice. Publication does not guarantee adoption. Regulatory approval does not mean clinicians will immediately feel confident using a new treatment or that patients and healthcare systems are ready to benefit from it.
The real challenge is turning evidence into understanding, confidence and, ultimately, action.
For adoption to happen, healthcare professionals need to understand the evidence, see its relevance to the problem they are trying to solve and be able to apply it in the real world.
And many of the factors determining whether that happens are established long before launch. Treatment pathways already exist. Diagnostic and referral processes are in place. Capacity may be constrained. Evidence expectations continue to evolve. Local access, funding and infrastructure all influence whether an innovation makes it into clinical practice.
This is where Medical Affairs can play a much bigger role.
Planning earlier, but also differently
The opportunity is not simply for Medical Affairs to become involved earlier. It is to challenge assumptions and ask smarter questions, sooner. What needs to change in clinical practice? Where does confidence need to build? What barriers could prevent adoption? Which stakeholders need to act differently? And what evidence, education or engagement will enable that change?
The direction of travel is already visible. The 2025 Medical Affairs Professional Society benchmark report on launch readiness found that Medical Affairs co-led launch preparation in 60% of the 28 surveyed organisations, with medical teams frequently becoming involved one to three years before launch.1 While the sample is relatively small, it points towards a broader shift to earlier medical leadership.
This earlier involvement creates an opportunity to understand the factors that will ultimately influence adoption including:
- Unresolved scientific and clinical questions
- Evidence gaps relevant to treatment decisions
- Patient-important outcomes
- Variations in care pathways and local practice
- Diagnostic and referral requirements
- Potential implementation barriers
- Educational needs across clinical communities.
This matters because adoption rarely depends on a single clinician making a decision in isolation.
Multidisciplinary teams, specialist nurses, pharmacists, payers, patient organisations, healthcare managers and service leaders can all influence how innovation is adopted. Each sees the challenge from a different perspective and needs different evidence, education and engagement.
From knowing to doing
Even when clinicians believe in a treatment, the healthcare system may not be ready to deliver it. Diagnostic pathways may need to change. Referral networks may not support a new treatment model. Capacity or infrastructure may be limited. Funding and local access policies may create additional barriers.
None of these factors make the science less compelling. But they can determine whether that science translates into better outcomes for patients.
Medical Affairs is uniquely positioned to connect these dots across the healthcare ecosystem, bringing together scientific, clinical, patient and real-world perspectives to understand not only what people need to know, but what needs to change.
That requires a different definition of launch readiness. The question isn’t simply: ‘Do we have enough evidence to launch?’ It is: ‘Do we understand what needs to change for that evidence to be acted upon in clinical practice?’
The future of Medical Affairs will not be defined only by the evidence it helps generate, but by what that evidence enables people to do differently. Because ultimately, scientific progress delivers its greatest value when it changes clinical practice and improves outcomes for patients.
Reference
- 2025 Medical Affairs Launch Readiness and Execution Benchmark Report, Medical Affairs Professional Society, 2025. Available at: https://medicalaffairs.org/benchmark-reports/2025-medical-affairs-launch-readiness-and-execution-benchmark-report/




